Autonomix Medical, Inc. announced it has received Ethics Committee approval of the protocol amendment for its ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. The primary objective of the PoC human clinical trial is to successfully ablate relevant nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region. As previously announced, a total of twenty-five (25) subjects will be treated in the trial, with the first five patients treated acting as ?lead-in?

patients to be treated according to protocol to ensure the physician?s familiarity with the procedure before enrolling the twenty (20) subjects that will be formally included in the study data results and analysis of trial objectives. Confirmation of suitability is determined by the primary oncologist caring for the patients with the treating Principal Investigator confirming eligibility for the study. Following the completion of treatment for the first five ?lead-in?

patients, Autonomix has amended the study protocol to include the gathering of additional information on tumor encroachment on the vessels, as well as other key bio-measurements that may correlate with effective nerve ablation. Additionally, the Company has further defined severe pain for inclusion criteria as a 7 or above on the VAS scale as indicated by the patient rather than physician determination. Autonomix commenced patient screening under the amended protocol in May 2024 and remains on track to complete enrollment in the PoC human clinical trial by year-end.

The Company?s catheter-based technology is being developed to do two things: sense neural signals associated with pain or disease and deliver targeted ablation to those nerves for treatment. Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body. The Company is initially developing its technology to address pancreatic cancer-related pain.

Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.